DGX insider files Rule 144 notice to sell 1,250 common shares

Rhea-AI Filing Summary

Quest Diagnostics (DGX) filed a notice under Rule 144 for a planned sale of common stock. The notice covers the proposed sale of 1,250 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 239700.00.

The shares to be sold were acquired from the issuer through restricted stock vesting on several dates in 2024 and through dividend reinvestment. Individual acquisitions listed include 211, 431 and 455 common shares from restricted stock vesting in May 2024, and 77 and 76 common shares from dividend reinvestment in July and October 2024, respectively. The notice also reports that 111,242,362 common shares were outstanding.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1250	239700.00	111242362	11/25/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/17/2024	Restricted Stock Vesting	Issuer			211	05/17/2024	Compensation
Common	05/18/2024	Restricted Stock Vesting	Issuer			431	05/18/2024	Compensation
Common	05/21/2024	Restricted Stock Vesting	Issuer			455	05/21/2024	Compensation
Common	07/19/2024	Dividend Reinvestment	Issuer			77	07/19/2024	Cash
Common	10/18/2024	Dividend Reinvestment	Issuer			76	10/18/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the DGX Form 144 filing disclose?

The Form 144 filing for Quest Diagnostics (DGX) discloses a proposed sale of 1,250 shares of the companys common stock under Rule 144 through a broker on the NYSE.

How many Quest Diagnostics (DGX) shares are planned to be sold and through which broker?

The notice states that 1,250 common shares of Quest Diagnostics are to be sold through Fidelity Brokerage Services LLC on the NYSE.

What is the aggregate market value of the DGX shares to be sold under this Form 144?

The filing lists an aggregate market value of 239700.00 for the 1,250 Quest Diagnostics common shares to be sold.

How were the Quest Diagnostics (DGX) shares being sold acquired?

The shares were acquired from the issuer through restricted stock vesting on several dates in May 2024 and through dividend reinvestment in July 2024 and October 2024.

What amounts of DGX stock were acquired in each listed transaction?

The filing lists acquisitions of 211, 431 and 455 common shares via restricted stock vesting on different May 2024 dates, and 77 and 76 common shares via dividend reinvestment in July and October 2024.

How many Quest Diagnostics (DGX) shares are reported as outstanding in the Form 144?

The Form 144 reports that 111,242,362 common shares of Quest Diagnostics were outstanding.

What representation does the seller make in the DGX Form 144 notice?

By signing the notice, the seller represents that they do not know any material adverse information about the issuers current or prospective operations that has not been publicly disclosed.